Steve Chriscoe

Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK Inhibitors - BioSpace The acquisition was featured Monday in Roche’s Pharma Day presentation, which also included projections of more than $3 billion in annual sales from three early-stage obesity and diabetes drugs. A portfolio of CDK inhibitors developed by Regor Pharmaceuticals has found a home at Roche, which announced Monday it would buy the investigational cancer drugs for $850 million upfront. Cambridge, Mass.– and China-based Regor will see two ongoing Phase I trials of CDK4 inhibitor RGT-419B through to their completion, at which time Roche’s Genentech subsidiary will take over global clinical development, manufacturing and commercialization of this asset. The deal also includes additional CDK4 inhibitors for cancer. Last December, Regor announced results from a Phase Ia trial of RGT-419B, showing that the drug was safe and well tolerated in patients with HR+/HER2- advanced breast cancer who have progressed on CDK4/6 inhibitors and endocrine therapy. “Monotherapy clinical efficacy” was also observed, Regor reported. The deal, which is expected to close in the fourth quarter of this year, includes the potential for Regor to claim additional cash payments based on the achievement of predetermined development, regulatory and commercial milestones. “Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world,” Xiayang Qiu, founder and CEO of Regor, said in a statement. https://lnkd.in/eU-gY4wQ

34

1 Comment

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

Join us on Wednesday, July 24 at 8:30 a.m. EDT for Mind the Gap: The Cost of Mental Health Disparities, a live discussion hosted by The Hill and sponsored by Otsuka. One in five U.S. adults live with a mental illness, yet access to treatment remains a challenge. This is especially true for lower-income individuals and minority populations who bear a disproportionate burden of both mental health and chronic conditions. According to the National Alliance on Mental Illness (NAMI), Non-Hispanic White adults (52%) are more than twice as likely to receive treatment for a mental illness compared to Asian Americans (25%). Those numbers increase modestly among the Hispanic or Latino (36%) and Black or African American (39%). What barriers prevent racial and ethnic minority groups, as well as other marginalized, rural, and under-resourced populations, from accessing treatment? What are the unique mental health needs of racially and ethnically diverse communities? What is the economic cost of not investing in mental health services, treatments, and programs? How can we change the conversation around minority mental health to reduce stigma and encourage more integrated, equitable care? In honor of Minority Mental Health Awareness Month, the Hill will bring together lawmakers, mental health experts and advocates to discuss these questions and more as they discuss the findings of the Meharry School of Global Health’s 2024 study, “The Projected Costs and Economic Impact of Mental Health Inequities in the United States.” Register for the event: https://bit.ly/4bzELN9 https://bit.ly/4cXHnpX

7